Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients. (Q46024732)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19417125%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

title

Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19417125%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19417125%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Monica Nannipieri

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19417125%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

7

Ele Ferrannini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19417125%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

author name string

Arturo Casolaro

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19417125%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Demetrio Ciociaro

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19417125%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Silvia Frascerra

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19417125%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Emma Buzzigoli

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19417125%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

publication date

5 May 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19417125%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Physiology - Endocrinology and Metabolism

27 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19417125%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

volume

297

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19417125%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19417125%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

page(s)

E225-30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19417125%20AND%20SRC:MED&resulttype=core&format=json

Overproduction of large VLDL particles is driven by increased liver fat content in man.

27 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90960.2008

The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90960.2008

Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90960.2008

Effects of pioglitazone on lipid and lipoprotein metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90960.2008

The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90960.2008

Acute and selective regulation of glyceroneogenesis and cytosolic phosphoenolpyruvate carboxykinase in adipose tissue by thiazolidinediones in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90960.2008

Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90960.2008

Role of lipid oxidation in pathogenesis of insulin resistance of obesity and type II diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90960.2008

Effect of pioglitazone on the metabolic and hormonal response to a mixed meal in type II diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90960.2008

Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90960.2008

A futile metabolic cycle activated in adipocytes by antidiabetic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90960.2008

Fuel selection in human skeletal muscle in insulin resistance: a reexamination

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90960.2008

The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90960.2008

Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90960.2008

Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90960.2008

Pioglitazone stimulates apolipoprotein A-I production without affecting HDL removal in HepG2 cells: involvement of PPAR-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90960.2008

A "futile cycle" induced by thiazolidinediones in human adipose tissue?

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90960.2008

The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90960.2008

Diabetic dyslipidaemia: from basic research to clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90960.2008

Fasting and daylong triglycerides in obesity with and without type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90960.2008

Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90960.2008

Rosiglitazone treatment increases subcutaneous adipose tissue glucose uptake in parallel with perfusion in patients with type 2 diabetes: a double-blind, randomized study with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90960.2008

Increased fat mass compensates for insulin resistance in abdominal obesity and type 2 diabetes: a positron-emitting tomography study

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90960.2008

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.90960.2008

10.1152/AJPENDO.90960.2008

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19417125%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

1 reference